ibi308 Combined With Bevacizumab + XELOX Regimen in Advanced Colorectal Cancer
Status:
Recruiting
Trial end date:
2023-12-12
Target enrollment:
Participant gender:
Summary
a phase II clinical study of IBI308 combined with bevacizumab + XELOX regimen in the
treatment of patients with metastatic colorectal cancer. a total of 8 courses of medication
would be given. A total of 25 patients are planned to be enrolled.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University